Kala Pharmaceuticals logo

Kala PharmaceuticalsNASDAQ: KALA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

20 July 2017

Next earnings report:

28 March 2025

Last dividends:

N/A

Next dividends:

N/A
$30.80 M
-78%vs. 3y high
30%vs. sector
-vs. 3y high
-vs. sector
-43%vs. 3y high
80%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 15 Nov 2024 21:09:00 GMT
$6.68-$0.08(-1.18%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

KALA Latest News

KALA BIO (KALA) Moves to Strong Buy: Rationale Behind the Upgrade
zacks.com09 October 2024 Sentiment: POSITIVE

KALA BIO (KALA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Does KALA BIO (KALA) Have the Potential to Rally 152.83% as Wall Street Analysts Expect?
Zacks Investment Research04 April 2024 Sentiment: POSITIVE

The mean of analysts' price targets for KALA BIO (KALA) points to a 152.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

KALA BIO (KALA) Reports Q3 Loss, Misses Revenue Estimates
Zacks Investment Research13 November 2023 Sentiment: NEGATIVE

KALA BIO (KALA) came out with a quarterly loss of $3.41 per share versus the Zacks Consensus Estimate of a loss of $2.15. This compares to earnings of $19.25 per share a year ago.

Wall Street Analysts Predict a 213.6% Upside in Kala Pharma (KALA): Here's What You Should Know
Zacks Investment Research24 March 2023 Sentiment: POSITIVE

The mean of analysts' price targets for Kala Pharma (KALA) points to a 213.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

What type of business is Kala Pharmaceuticals?

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

What sector is Kala Pharmaceuticals in?

Kala Pharmaceuticals is in the Healthcare sector

What industry is Kala Pharmaceuticals in?

Kala Pharmaceuticals is in the Biotechnology industry

What country is Kala Pharmaceuticals from?

Kala Pharmaceuticals is headquartered in United States

When did Kala Pharmaceuticals go public?

Kala Pharmaceuticals initial public offering (IPO) was on 20 July 2017

What is Kala Pharmaceuticals website?

https://www.kalarx.com

Is Kala Pharmaceuticals in the S&P 500?

No, Kala Pharmaceuticals is not included in the S&P 500 index

Is Kala Pharmaceuticals in the NASDAQ 100?

No, Kala Pharmaceuticals is not included in the NASDAQ 100 index

Is Kala Pharmaceuticals in the Dow Jones?

No, Kala Pharmaceuticals is not included in the Dow Jones index

When was Kala Pharmaceuticals the previous earnings report?

No data

When does Kala Pharmaceuticals earnings report?

The next expected earnings date for Kala Pharmaceuticals is 28 March 2025